Newswire (Published: Tuesday, February 7, 2017, Received: Thursday, February 2, 2017, 4:46:27 PM CST)

Word Count: 394

Data on Prostate Cancer Reported by S.Y. Ku and Co-Researchers (Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance)

By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating in Buffalo, New York, by NewsRx journalists, research stated, "Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology with altered lineage marker expression, suggesting that lineage plasticity facilitates therapeutic resistance. The mechanisms underlying prostate cancer lineage plasticity are incompletely understood."

The news reporters obtained a quote from the research, "Studying mouse models, we demonstrate that Rb1 loss facilitates lineage plasticity and metastasis of prostate adenocarcinoma initiated by Pten mutation. Additional loss of Trp53 causes resistance to antiandrogen therapy. Gene expression profiling indicates that mouse tumors resemble human prostate cancer neuroendocrine variants; both mouse and human tumors exhibit increased expression of epigenetic reprogramming factors such as Ezh2 and Sox2. Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandrogen therapy."

According to the news reporters, the research concluded: "These findings uncover genetic mutations that enable prostate cancer progression; identify mouse models for studying prostate cancer lineage plasticity; and suggest an epigenetic approach for extending clinical responses to antiandrogen therapy."

For more information on this research see: Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 2017;355(6320):78-83. Science can be contacted at: Amer Assoc Advancement Science, 1200 New York Ave, NW, Washington, DC 20005, USA. (Springer - www.springer.com; Science - www.springerlink.com/content/0926-7220/)

Our news correspondents report that additional information may be obtained by contacting L. Ellis, RPCI, Dept. of Pharmacol & Therapeut, Buffalo, NY 14263, United States. Additional authors for this research include S. Rosario, Y.Q. Wang, P. Mu, M. Seshadri, Z.W. Goodrich, M.M. Goodrich, D.P. Labbe, E.C. Gomez, J.M. Wang, H.W. Long, B. Xu, M. Brown, M. Loda, C.L. Sawyers, L. Ellis and D.W. Goodrich (see also Oncology - Prostate Cancer).

Keywords for this news article include: Buffalo, New York, United States, North and Central America, Prostatic Neoplasms, Prostate Cancer, Oncology, Genetics, Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Central America
North America
United States
Americas
District of Columbia
New York
Washington
D.C.
Buffalo

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Genetics